Literature DB >> 2802661

Soluble Il-2 receptor serum levels--a marker for disease progression in patients with HIV-1 infection.

C Schulte1, M Meurer.   

Abstract

Serum levels of soluble Il-2 receptors (sIl-2R) were measured in 88 patients with HIV infection, 28 patients from high-risk groups, and 28 normal donors. Elevated sIl-2R levels were found in 46% of asymptomatic seropositive patients, in 68% of patients with persistent generalized lymphadenopathy, and in 81% of patients with AIDS. Mean sIl-2R values increased with the progression of the disease and were most pronounced in patients with AIDS. A close correlation was found between sIl-2R levels and beta2-microglobulin (p less than 0.0001) and other prognostic parameters known to parallel clinical activity. In addition to being a valuable parameter in monitoring the course of the HIV infection, elevated sIl-2R levels may also be involved in the down-regulation of Il-2-dependent immune functions in AIDS.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2802661     DOI： 10.1007/bf00412971

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN： 0340-3696            Impact factor:   3.017


  31 in total

1.  Elevated titers of cell-free interleukin-2 receptor in serum and cerebrospinal fluid specimens of patients with acquired immunodeficiency syndrome.

Authors:  K K Sethi; H Näher
Journal:  Immunol Lett       Date:  1986-10       Impact factor: 3.685

2.  Beta 2-microglobulin as a prognostic marker for development of AIDS.

Authors:  R B Bhalla; B Safai; S Pahwa; M K Schwartz
Journal:  Clin Chem       Date:  1985-08       Impact factor: 8.327

3.  Inhibition of interleukin-2-induced T-cell proliferation by sera from patients with the acquired immune deficiency syndrome.

Authors:  R P Donnelly; K Y Tsang; G M Galbraith; J I Wallace
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

4.  Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro.

Authors:  K Y Tsang; H H Fudenberg; G M Galbraith; R P Donnelly; L R Bishop; W R Koopmann
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

5.  Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

Authors:  R Lafreniere; S A Rosenberg
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

6.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells.

Authors:  R Suzuki; K Handa; K Itoh; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

7.  Characterization of immunologic function in homosexual men with persistent, generalized lymphadenopathy and acquired immune deficiency syndrome.

Authors:  R L Burkes; W Abo; A M Levine; M Linker-Israeli; J W Parker; P S Gill; M Krailo; D A Horwitz
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

8.  Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.

Authors:  A H Rook; H Masur; H C Lane; W Frederick; T Kasahara; A M Macher; J Y Djeu; J F Manischewitz; L Jackson; A S Fauci; G V Quinnan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  Activation of virus specific CTL clones: antigen-dependent regulation of interleukin 2 receptor expression.

Authors:  M E Andrew; A M Churilla; T R Malek; V L Braciale; T J Braciale
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422
View more
  4 in total

1.  Factors influencing serum neopterin and beta 2-microglobulin levels in a healthy diverse population.

Authors:  L S Diamondstone; D J Tollerud; D Fuchs; H Wachter; L M Brown; E Maloney; C C Kurman; D L Nelson; W A Blattner
Journal:  J Clin Immunol       Date:  1994-11       Impact factor: 8.317

2.  Utility of Serum Neopterin and Serum IL-2 Receptor Levels to Predict Absolute CD4 T Lymphocyte Count in HIV Infected Cases.

Authors:  Sanjim Chadha; Preena Bhalla; Hitender Gautam; Anita Chakravarti; Sanjeev Saini; S Anuradha; Richa Dewan
Journal:  Interdiscip Perspect Infect Dis       Date:  2013-12-05

Review 3.  Myeloid-derived suppressor cells and the pathogenesis of human immunodeficiency virus infection.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani
Journal:  Open Biol       Date:  2021-11-10       Impact factor: 6.411

4.  The soluble form of the EIAV receptor encoded by an alternative splicing variant inhibits EIAV infection of target cells.

Authors:  Yue-Zhi Lin; Fei Yang; Shu-Qin Zhang; Liu-Ke Sun; Xue-Feng Wang; Cheng Du; Jian-Hua Zhou
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.